Autolus Therapeutics plc
AUTL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001730463
In the last 90 days, Autolus Therapeutics plc insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $212.0M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Autolus Therapeutics plc changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 66 | 2 | 67 | +3 |
| Shares | 53.0M | 58.8K | 50.8M | −2.12M (−4.0%) |
| Value | $228.6M | $245.0K | $143.9M | −$84.5M (−37.0%) |
2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (14)
Institutions that held Autolus Therapeutics plc at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Oconnor LLC | 584,246 | $1.65M | 0.02% |
| MAI Capital Management | 365,407 | $1.03M | 0.02% |
| ExodusPoint Capital Management, LP | 149,035 | $422.0K | 0.01% |
| Acadian Asset Management LLC | 34,888 | $98.0K | 0.00% |
| Cubist Systematic Strategies, LLC | 21,487 | $61.0K | 0.00% |
| Bayshore Asset Management, LLC | 17,500 | $50.0K | 0.04% |
| Susquehanna International Group, LLP | 16,617 | $47.0K | 0.00% |
| Jane Street Group, LLC | 14,717 | $42.0K | 0.00% |
| Renaissance Technologies LLC | 12,800 | $36.0K | 0.00% |
| Cannell Capital LLC | 4,001 | $11.0K | 0.00% |
| Total Clarity Wealth Management, Inc. | 1,200 | $3.00K | 0.00% |
| BNP Paribas Arbitrage, SA | 1,010 | $2.86K | 0.00% |
| Northwestern Mutual Wealth Management Co | 500 | $1.00K | 0.00% |
| Curi Capital | 137 | $0 | 0.00% |
Sold out (11)
Institutions that held Autolus Therapeutics plc at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Deep Track Capital, LP | 382,559 | $1.59M |
| Eversept Partners, LP | 371,540 | $1.55M |
| Virtus ETF Advisers LLC | 27,536 | $115.0K |
| Moloney Securities Asset Management, LLC | 20,000 | $83.0K |
| Barclays PLC | 15,074 | $63.0K |
| Gsa Capital Partners LLP | 11,869 | $49.0K |
| Quadrant Capital Group LLC | 3,087 | $13.0K |
| High Net Worth Advisory Group LLC | 2,000 | $8.00K |
| Parallel Advisors, LLC | 982 | $4.00K |
| US Bancorp | 301 | $1.00K |
| Signaturefd, LLC | 346 | $1.00K |
Not filed for Q2 2022 yet (2)
Institutions that held Autolus Therapeutics plc at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Susquehanna Fundamental Investments, LLC | 48,250 | $201.0K |
| Golden State Equity Partners | 10,555 | $44.0K |